|Systematic (IUPAC) name|
1-[(3,4-Dimethoxyphenyl)methyl]-2-[10-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]decyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium methyl sulfate
|Molar mass||1077.35 g/mol|
|(what is this?)|
Laudexium metilsulfate is a neuromuscular blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in surgical anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Laudexium is no longer used in clinical practice, though it was introduced clinically in the early 1950s. It has about half the potency, a slower onset of action and a duration of action much longer than that of d-tubocurarine. As with all clinically established (as well as experimental agents) with a non-depolarizing mechanism of action, its pharmacological action can be antagonized by anticholinesterases.
The displacement of laudexium from clinical use was assured owing to recurrent reports of significant post-operative re-curarization.
- Taylor EP (1952). "Synthetic neuromuscular blocking agents. Part II. Bis(quaternary ammonium salts) derived from laudanosine". J Chem Soc: 142–145. doi:10.1039/JR9520000142.
- Hunter AR (1955). "The action of laudexium in man and experimental animals". Br J Anaesth. 27 (2): 73–79. doi:10.1093/bja/27.2.73. PMID 13230365.
- Collier HO, Macauley B (1952). "The pharmacological properties of "laudolissin" a long-acting curarizing agent". Br J Pharmacol Chemother. 7 (3): 398–408. doi:10.1111/j.1476-5381.1952.tb00707.x. PMC . PMID 12978243.